CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression - PubMed (original) (raw)
Comparative Study
doi: 10.1002/cyto.b.20106.
Affiliations
- PMID: 16568475
- DOI: 10.1002/cyto.b.20106
Free article
Comparative Study
CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression
Joke G Boonstra et al. Cytometry B Clin Cytom. 2006 May.
Free article
Abstract
Background: Increased CD38 expression by leukemic cells has been suggested as an adverse prognostic factor in B-CLL. Several approaches have been proposed to quantify its level of expression by flow cytometry.
Methods: We compared the use of (i) the percentage of CD38 positive cells, (ii) CD38 antibodies bound per cell (ABC), and (iii) a semi-quantitative method based on the shape of the CD38 histogram, within a cohort of 78 B-CLL patients.
Results: A decreased overall survival was seen with >30% CD38 positivity among B-CLL cells, with CD38 ABC >100, and with bimodal or unimodal, strongly positive CD38 histograms. However, patients with unimodal weakly positive CD38 histograms also showed a significantly reduced survival as did patients with intermediate proportions (i.e. 5-30%) of CD38+ cells. Furthermore, within the group with <5% CD38 positivity among their B-CLL cells, 84% of patients showed prognostically favourable mutated IGVH gene segments and 100% had low ZAP70 gene expression. For 5-30% CD38 positivity, these proportions were 50 and 83%, while for >30% CD38 positivity, these proportion were only 28 and 56%, respectively.
Conclusions: We found a simple method of quantitation of CD38 expression (i.e., >5% CD38 positivity among B-CLL cells) to be sufficient to identify patients with an unfavourable prognosis. The level of CD38 expression as defined with this method correlated well with the IGVH mutation status and ZAP70 gene expression.
Copyright 2006 International Society for Analytical Cytology.
Similar articles
- Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Gachard N, Salviat A, Boutet C, Arnoulet C, Durrieu F, Lenormand B, Leprêtre S, Olschwang S, Jardin F, Lafage-Pochitaloff M, Penther D, Sainty D, Reminieras L, Feuillard J, Béné MC; GEIL. Gachard N, et al. Haematologica. 2008 Feb;93(2):215-23. doi: 10.3324/haematol.11622. Epub 2008 Jan 26. Haematologica. 2008. PMID: 18223290 - T-cell CD38 expression in B-chronic lymphocytic leukaemia.
Abousamra NK, El-Din MS, Azmy E. Abousamra NK, et al. Hematol Oncol. 2009 Jun;27(2):82-9. doi: 10.1002/hon.877. Hematol Oncol. 2009. PMID: 19247976 - Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Dührsen U, Dürig J. Schroers R, et al. Leukemia. 2005 May;19(5):750-8. doi: 10.1038/sj.leu.2403707. Leukemia. 2005. PMID: 15759031 - New prognostic markers in chronic lymphocytic leukemia.
Moreno C, Montserrat E. Moreno C, et al. Blood Rev. 2008 Jul;22(4):211-9. doi: 10.1016/j.blre.2008.03.003. Epub 2008 Apr 29. Blood Rev. 2008. PMID: 18448218 Review. - Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.
Rassenti LZ, Kipps TJ. Rassenti LZ, et al. Cytometry B Clin Cytom. 2006 Jul 15;70(4):209-13. doi: 10.1002/cyto.b.20129. Cytometry B Clin Cytom. 2006. PMID: 16906583 Review. No abstract available.
Cited by
- Flow Cytometric Expression of CD49d in Newly Diagnosed Chronic Lymphocytic Leukemia and Its Correlation with Established Prognostic Markers.
Kunnumbrath A, Singh N, Gupta AK, Chowdhury N, Nath UK, Chandra H. Kunnumbrath A, et al. J Lab Physicians. 2022 Jun 10;14(4):435-442. doi: 10.1055/s-0042-1748828. eCollection 2022 Dec. J Lab Physicians. 2022. PMID: 36531546 Free PMC article. - The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.
Zeidler JD, Hogan KA, Agorrody G, Peclat TR, Kashyap S, Kanamori KS, Gomez LS, Mazdeh DZ, Warner GM, Thompson KL, Chini CCS, Chini EN. Zeidler JD, et al. Am J Physiol Cell Physiol. 2022 Mar 1;322(3):C521-C545. doi: 10.1152/ajpcell.00451.2021. Epub 2022 Feb 9. Am J Physiol Cell Physiol. 2022. PMID: 35138178 Free PMC article. Review. - Establishing CD19 B-cell reference control materials for comparable and quantitative cytometric expression analysis.
Wang L, Bhardwaj R, Mostowski H, Patrone PN, Kearsley AJ, Watson J, Lim L, Pichaandi J, Ornatsky O, Majonis D, Bauer SR, Degheidy HA. Wang L, et al. PLoS One. 2021 Mar 19;16(3):e0248118. doi: 10.1371/journal.pone.0248118. eCollection 2021. PLoS One. 2021. PMID: 33740004 Free PMC article. - Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.
Butler T, Gribben JG. Butler T, et al. Blood Rev. 2010 May;24(3):135-41. doi: 10.1016/j.blre.2010.03.004. Epub 2010 Apr 15. Blood Rev. 2010. PMID: 20398985 Free PMC article. Review. - How I treat CLL up front.
Gribben JG. Gribben JG. Blood. 2010 Jan 14;115(2):187-97. doi: 10.1182/blood-2009-08-207126. Epub 2009 Oct 22. Blood. 2010. PMID: 19850738 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials